AbCellera has reached a settlement and patent license agreement with Bruker Corporation, concluding global patent litigation.
Bruker Corporation will pay AbCellera $36 million upfront and future royalties on sales of Beacon® Optofluidic platform products.
Focused on antibody-based medicines, AbCellera operates in endocrinology, women's health, immunology, and oncology.
Settlement Agreement
Bruker Corporation to pay AbCellera $36 million upfront and future royalties on sales of Beacon® Optofluidic products.
Business Focus
AbCellera specializes in discovering and developing antibody-based medications across various medical fields.
Legal Resolution
The settlement marks the end of global patent litigation between AbCellera and Bruker Corporation.
- This settlement is a significant financial gain for AbCellera, providing an upfront payment and ongoing royalties.
- The agreement with Bruker Corporation solidifies AbCellera's position in the biotechnology industry, enhancing its financial stability and growth potential.
The settlement and patent license agreement between AbCellera and Bruker Corporation mark a positive milestone for AbCellera, securing financial benefits and paving the way for future collaborations in the biotechnology sector.